IL13 and non-small cell lung carcinoma: demonstrated by in vitro and in vivo experiments that PG2 dose-dependently and significantly increased the polarization ratio of M1 macrophages and down-regulated IL-4- and IL-13-induced M2 polarization in non-small cell lung cancer (NSCLC) (93).